Question: represent this title to get a news article that provides more details about it

Question: Dick Clark Productions rejects Mariah Carey’s 'absurd' sabotage claim

represent the article to find a fitting news title!

The provided query could be "['Represent this text to find a news title for it', 'A rally with white nationalists chanting phrases like "Jews will not replace us" and "end immigration, one people, one nation" was, as many expressed online, disturbing yet not really all that surprising.\nWithin hours of the tragedy in Charlottesville, journalists, scholars and other leading voices weighed in around the Internet, with analysis and deeper understanding of how this unfolded.\nBelow are some of the most revealing pieces we read.\nHere at Code Switch, my teammate Gene Demby wrote about about how white nationalists are edging their movement out of the shadows:\n"Richard Spencer, the white nationalist leader and University of Virginia alum who coined the term \'alt-right,\' would likely count that openness as its own incremental success. \'If you greeted someone in 1985 and you said, \'all gays should marry,\' you actually would get a lot of laughs,\' Spencer told The Atlantic last year, not long after the election. \'By 2015, gay marriage is popular. What is possible has shifted. That\'s what the alt-right is doing. It\'s shifting the reality of what\'s possible, and imagining a reality in which they are.\' "\nCode Switch alum Matt Thompson, now executive editor at The Atlantic, riffed on the brazenness of the white supremacists who marched this weekend, compared with Klan members of decades past who hid under white hoods. "The shameless return of white supremacy into America\'s public spaces seems to be happening by degrees, and quickly," Thompson wrote.\nDara Lind, a reporter at Vox who wrote an explainer of the rally and its origins, described it as a "coming-out party for resurgent white nationalism in America."\nNathan Guttman, a reporter with Forward, an online news site aimed at Jewish Americans, penned a vivid piece about covering the march. He recounted watching as Spencer launched into a rant about the mayor of Charlottesville, Michael Signer.\n" \'[L]ittle Mayor Signer — SEE-NER — how do you pronounce this little creep\'s name?\' asked Richard Spencer, a right-wing leader who dreams of a \'white ethnostate,\' as he stood on a bench under a tree to rally his troops, deprived of their protest. The crowd knew exactly how to pronounce his name: \'Jew, Jew, Jew, Jew\' some shouted out. The rest burst out in laughter. And that was one of the only moments of levity the alt-right audience gathered under the tree enjoyed."\nAnd Jia Tolentino, a writer for The New Yorker and a graduate of the University of Virginia, meditated on Charlottesville\'s progressive guise and ability to hide its dark racial past. "While I was at U.V.A., the fact that slaves had built the school was hardly discussed, and the most prominent acknowledgment that Jefferson was a slave owner came on Valentine\'s Day, when signs went up all over campus that said \'TJ ♥s Sally.\' "\nMany writers also took on the response from President Trump, whose initial reaction to the violence in Charlottesville condemned equally both sides of the protest. "We condemn in the strongest possible terms this egregious display of hatred, bigotry and violence on many sides," Trump said, in remarks that brought condemnation from both Democrats and Republicans.\nWriting for The New Yorker, Jelani Cobb parsed Trump\'s initial response further:\n"We have seen a great number of false equivalencies in the past two years, and the most recent Presidential election was defined by them. Yet it remains striking to hear Trump imply that Nazis and the interracial group of demonstrators who gathered to oppose them were, in essence, equally wrong. It would have been naïve to expect the President to unambiguously condemn neo-Confederates ("Heritage, not hate," etc.), but Nazis? For reasons that are not hard to discern, the swastika, at least in the United States, has always been more clearly legible as a symbol of racial bigotry than the Confederate flag."\nMichael Gerson, a former speechwriter for President George W. Bush, lambasted Trump in a Washington Post piece, writing that the current president was "incapable" of speaking for the nation in the face of tragedy:\n"If great words can heal and inspire, base words can corrupt. Trump has been delivering the poison of prejudice in small but increasing doses. In Charlottesville, the effect became fully evident. And the president had no intention of decisively repudiating his work. What do we do with a president who is incapable or unwilling to perform his basic duties? What do we do when he is incapable of outrage at outrageous things? What do we do with a president who provides barely veiled cover for the darkest instincts of the human heart? These questions lead to the dead end of political realism — a hopeless recognition of limited options. But the questions intensify."\nOn Monday, Trump responded to the increasing pressure to respond more forcefully, and gave a stronger rebuke. "Racism is evil," Trump said. "And those who cause violence in its name are criminals and thugs, including the K.K.K., neo-Nazis, white supremacists and other hate groups that are repugnant to everything we hold dear as Americans."\nIn a piece for Commentary Magazine, John Podhoretz, a former speechwriter for Presidents Ronald Reagan and George H.W. Bush, cast a skeptical eye toward Trump\'s remarks on Monday:\n"You can choose to have whatever opinion you have on the president\'s statement today condemning white supremacists, but it\'s hard to believe he would have read it out if he\'d had his druthers. No, the real Donald Trump was the one we saw on Saturday when he decided to condemn violence \'on many sides\' in response to the deliberately provocative and intentionally violent neo-Nazi march in Charlottesville, Virginia; when he decided to refer to the events as \'sad\' in tweets; when he wished \'best regards\' to those injured by the car that was deliberately smashed into them, killing 1 and injuring 20. When he acted in that way, he was operating according to his instinct. And his instinct said: Do not attack the white supremacists."\nWhat Trump\'s comments Monday mean for how, exactly, he will handle the resurgence of white supremacists, remains unclear.\nAs Maggie Haberman of The New York Times tweeted shortly after Trump\'s remarks on Monday:']" and the positive "['Represent this title to get a news article that provides more details about it', "Making Sense Of Charlottesville: A Reader's Guide"]"

NEW YORK — Dick Clark Productions is hitting back against Mariah Carey’s claim it sabotaged her live performance on its “New Year’s Rockin’ Eve” special.
Carey’s disaster during the annual New Year’s Eve special in Times Square made international headlines: The superstar vocally stumbled through her short set, failing to sing for most of it despite a pre-recorded track of her songs playing in the background.
Carey was visibly upset during the performance and afterward tweeted “(expletive) happens.” Her representative Nicole Perna blamed technical difficulties, and in an interview with Billboard she said Dick Clark Productions hampered Carey’s performance.
Shit happens 😩 Have a happy and healthy new year everybody!🎉 Here's to making more headlines in 2017 😂 pic.twitter.com/0Td8se57jr — Mariah Carey (@MariahCarey) January 1, 2017
“She was not winging this moment and took it very seriously,” Perna told Billboard. “A shame that production set her up to fail.”
Perna said Carey’s earpiece wasn’t working and she flagged the issue to the production team but was told it would be OK when she got on stage.
“However, that was not the case, and they were again told that her earpiece was not working,” Perna said. “Instead of endeavouring to fix the issue so that Mariah could perform, they went live.”
In a statement released on Sunday, the production company called such claims “absurd.”
“As the premier producer of live television events for nearly 50 years, we pride ourselves on our reputation and long-standing relationships with artists,” it said. “To suggest that dcp (Dick Clark Productions), as producer of music shows including the American Music Awards, Billboard Music Awards, New Year’s Rockin’ Eve and Academy of Country Music Awards, would ever intentionally compromise the success of any artist is defamatory, outrageous and frankly absurd.”
It said that in “very rare instances” there are technical errors that can occur with live television. It said an initial investigation, however, indicated it had no involvement in the challenges associated with Carey’s performance.
“We want to be clear that we have the utmost respect for Ms. Carey as an artist and acknowledge her tremendous accomplishments in the industry,” it said.
A person familiar with the production of the show who asked for anonymity to speak publicly about the incident said all of the other performers, including Gloria Estefan, rehearsed onsite for their performances and Carey was there but had a stand-in for her rehearsal, atypical for the show’s performers. The person said all of the monitors were working and no technical problems were found.
Ironically, Carey was Dick Clark Productions’ first live performer for the broadcast in 2005, when it went off without any such problems.

Mariah Carey's former manager threatens to sue, claims singer sexually harassed her
Just a year ago, Mariah Carey was on such good terms with her then-manager, Stella Bulochnikov-Stolper, that she threw her a birthday party where she presented her with a $34,000 Louis Vuitton trunk as a gift. Shortly after the bash, Mariah unexpectedly fired Stella, along with a slew of other longtime employees. Now, Stella's going after Mimi for money she believes she's owed from their long-running, now defunct professional relationship, which she claims was cut short by the firing. Stella recently filed documents announcing she intends to sue Mariah for violation of the U.S. Civil Rights Act, a Violation of the Fair Employment and Housing Act and breach of contract, according to TMZ. The suit reportedly hinges on "a huge amount of money" Stella says she's still owed for her work. The website also reports Stella says she was sexually harassed by Mariah, whom she claims was regularly naked around her and "did sexual things in [Stella's] presence." Finally, Stella has reportedly accused Mariah of having a substance abuse problem and failing to take her medication for bipolar disorder. A rep for Mariah has already denied Stella's assertions are valid, telling TMZ: "If this frivolous and baseless claim is filed, we will defend against it vigorously and successfully."
RELATED: Mariah Carey's highs and lows


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Rays' Eovaldi stellar in return from Tommy John surgery

Represent the article to find a fitting news title

Eovaldi last pitched in the majors on Aug. 10, 2016, for the Yankees. Nine days later, he underwent a second elbow surgery. Eovaldi also had Tommy John surgery in 2007 when he was a junior in high school.
The 28-year-old missed the first month of this season after undergoing surgery March 30 to remove loose bodies in his elbow. Eovaldi made four rehab starts in the minors before being activated off the disabled list before Wednesday's game.
"It felt great being out there," Eovaldi said. "I was so focused on just getting that first out. After I got it, the emotions kind of got to me. I was a little nervous out there. Then I was able to regroup and slow back down."
Eovaldi, the 12th pitcher in major league history to start in the majors after having two Tommy John surgeries, induced seven groundouts and retired the final 17 batters he faced following the walk to Chapman.
"I think we pushed him about as much as we wanted to," Cash said.
Font then came in and retired Chapman on a liner to shortstop in the seventh before Lowrie pushed a single up the middle.
Nuno replaced Font in the ninth and gave up a leadoff walk to Chad Pinder, then retired the next three batters.
That was all the offence the A's could muster while being shut out by the Rays for the second time in three games.
"Honestly, those guys over there, they're pitching great," Oakland shortstop Chad Pinder said. "Those guys aren't a walk in the park, and they're locating and they're making all their pitches work. Hitting's hard enough as it is."
Oakland went into the game batting .216 in May, the second-lowest average in the majors.
STRUGGLING SEAN
Manaea allowed four runs in five innings. After going 4-1 with 1.00 ERA through his first six starts that included the majors' first no-hitter this season on Apri 21, the big left-hander has been in a tailspin.
TRAINER'S ROOM
Athletics: INF Marcus Semien was placed on the paternity leave list before the game. Pinder started at shortstop in Semien's absence. RHP Josh Lucas was called up from Triple-A Nashville. ... RHP Liam Hendriks began a rehab assignment with Triple-A Nashville.
UP NEXT
Tampa Bay RHP Ryne Stanek (1-0, 3.24 ERA) will make his second career start, three days after getting a win coming out of the bullpen. RHP Daniel Mengden (5-4, 2.85) goes for Oakland.
___
More AP baseball:https://apnews.com/tag/MLBbaseball
By Michael Wagaman, The Associated Press

The game had a rare 4:10 p.m. start time as part of a team marketing experiment. An estimated 2,000 fans witnessed the first pitch in sunny, 59-degree weather. The announced attendance was 10,761.
IN DANNY'S CORNER
Former Mariners teammates and their wives remained in contact with the family of White Sox RHP Danny Farquhar, who underwent surgery for a brain aneurysm last weekend. He spent the 2013-15 seasons with the team.
"You just want to give his family enough space, but you also want to do all you can to be there for support," said C Mike Zunino, Farquhar's ex-batterymate. "When you first hear something like this happens, it's really scary because you have don't know what's going to happen. It seems like each day we hear something positive, so that's a really good feeling."
TRAINER'S ROOM
Mariners: 1B Ryon Healy (sprained right ankle) neared his return from the disabled list with a two-run single and walk in four plate appearances for Double-A Arkansas Tuesday.
White Sox: LHP Carlos Rodon (left shoulder surgery) pitched three innings Monday against the Reds in an extended spring game in Arizona. He could rejoin the parent club in late May.
UP NEXT
Mariners: RHP Felix Fernandez (2-2, 5.06 ERA) will take a career 6-6 mark vs. the White Sox into the series finale Wednesday. He was a 4-3 winner in his only appearance against them last year.
White Sox: RHP James Shields (1-2, 6.17) comes off his worst start of the season, a 10-0 blowout against the Houston Astros in which he allowed seven earned runs in 5 1/3 innings.
By Paul Ladewski, The Associated Press


Question: Represent this title to get a news article that provides more details about it

Question: Dick Clark Productions rejects Mariah Carey's sabotage claim

Represent this text to find a news title for it:

NEW YORK – Dick Clark Productions is hitting back against Mariah Carey's claim it sabotaged her live performance on its "New Year's Rockin' Eve" special.
Carey's disaster during the annual New Year's Eve special in Times Square made international headlines: The superstar vocally stumbled through her short set, failing to sing for most of it despite a pre-recorded track of her songs playing in the background.
Carey was visibly upset during the performance and afterward tweeted "(expletive) happens." Her representative Nicole Perna blamed technical difficulties, and in an interview with Billboard she said Dick Clark Productions hampered Carey's performance.
"She was not winging this moment and took it very seriously," Perna told Billboard. "A shame that production set her up to fail."
Perna said Carey's earpiece wasn't working and she flagged the issue to the production team but was told it would be OK when she got on stage.
"However, that was not the case, and they were again told that her earpiece was not working," Perna said. "Instead of endeavoring to fix the issue so that Mariah could perform, they went live."
In a statement released on Sunday, the production company called such claims "absurd."
"As the premier producer of live television events for nearly 50 years, we pride ourselves on our reputation and long-standing relationships with artists," it said. "To suggest that dcp (Dick Clark Productions), as producer of music shows including the American Music Awards, Billboard Music Awards, New Year's Rockin' Eve and Academy of Country Music Awards, would ever intentionally compromise the success of any artist is defamatory, outrageous and frankly absurd."
It said that in "very rare instances" there are technical errors that can occur with live television. It said an initial investigation, however, indicated it had no involvement in the challenges associated with Carey's performance.
"We want to be clear that we have the utmost respect for Ms. Carey as an artist and acknowledge her tremendous accomplishments in the industry," it said.
A person familiar with the production of the show who asked for anonymity to speak publicly about the incident said all of the other performers, including Gloria Estefan, rehearsed onsite for their performances and Carey was there but had a stand-in for her rehearsal, atypical for the show's performers. The person said all of the monitors were working and no technical problems were found.
Ironically, Carey was Dick Clark Productions' first live performer for the broadcast in 2005, when it went off without any such problems.

represent this text to find a news title for it


Question: Represent this title to get a news article that provides more details about it

Question: New Study Finds Nearly 1 In 4 Americans Under The Age of 30 Is An Alcoholic

This news article should be represented to find a fitting news title

Advertisement - Continue Reading Below
According to a study recently published in JAMA Psychiatry, one in eight American adults now meets the diagnostic criteria for alcoholism. Further, nearly one in four adults under age 30 met the diagnostic criteria for alcoholism.
The study also found that rates of alcoholism were higher among men (16.7 percent), Native Americans (16.6 percent), people below the poverty threshold (14.3 percent), and people living in the Midwest (14.8 percent).
Most Popular
The data used in the study comes from National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), which was administered by the National Institutes of Health.
To meet the diagnostic criteria for alcoholism, a person must either fit the criteria of alcohol abuse or alcohol dependence.
For alcohol abuse, a person must exhibit at least one of the following things (from this National Institutes of Health list) in the past year:
Recurrent use of alcohol resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences or poor work performance related to alcohol use; alcohol-related absences, suspensions, or expulsions from school; neglect of children or household).
Recurrent alcohol use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by alcohol use).
Recurrent alcohol-related legal problems (e.g., arrests for alcohol-related disorderly conduct).
Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol (e.g., arguments with spouse about consequences of intoxication).
For alcohol dependence, an individual must experience at least three of the following seven symptoms from this National Institutes of Health list:
Need for markedly increased amounts of alcohol to achieve intoxication or desired effect; or markedly diminished effect with continued use of the same amount of alcohol.
The characteristic withdrawal syndrome for alcohol; or drinking (or using a closely related substance) to relieve or avoid withdrawal symptoms.
Drinking in larger amounts or over a longer period than intended.
Persistent desire or one or more unsuccessful efforts to cut down or control drinking.
Important social, occupational, or recreational activities given up or reduced because of drinking.
A great deal of time spent in activities necessary to obtain, to use, or to recover from the effects of drinking.
Continued drinking despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to be caused or exacerbated by drinking.
Disturbingly, alcohol use disorder rose by 49-percent in the first decade of the 2000s, and now affects 12.7-percent of the American population.
The study's lead author, Bridget Grant, a researcher at the National Institutes of Health, talked about the reason she believes there was an increase. "I think the increases are due to stress and despair and the use of alcohol as a coping mechanism."
The Centers for Disease Control and Prevention estimates 88,000 people die every year of alcohol-related causes.
Follow Delish on Instagram.
Download the Delish app.

This is fantastic !!! Everyone wanted to be a Toys R’ Us kid right?
RELATED CONTENT
The U.S. Released Its First Ever Pink Coin, and Raised $4 Million for Breast Cancer Research in One Day
Little Caesars Offered Free Pizza For Everyone If a 16-Seed Beat a 1-Seed in March Madness . . . and It Actually Happened
Two Guys Try to Use Spaghetti Sauce to Start a Fire After a Burglary
The Virgin “Idol” Contestant Did Not Want Katy Perry to Be His First Kiss
A Guy Followed His Mom’s Lottery Advice and Won $100,000
Wednesday Edition of Things that make you go hmmmmmm


Question: i found this news title. can you represent it to find an explanatory news article?:

Question: Sri Lankan PM says failed asylum seekers safe to return home

The Sri Lankan Prime Minister Ranil Wickremesinghe. (source: AP) The Sri Lankan Prime Minister Ranil Wickremesinghe. (source: AP)
Sri Lankan Prime Minister Ranil Wickremesinghe said on Wednesday that failed asylum seekers held in Australian-run detention centres in the South Pacific will not face prosecution or harm if they return home.
Wickremesinghe’s comment comes as Australia increases pressure on failed asylum seekers on Papua New Guinea’s Manus island and the tiny island nation of Nauru to return home voluntarily, including offering large sums of money, amid fears a deal for the United States to take refugees has collapsed. Only five men from Nepal on Manus have so far opted to leave despite the threat of deportations.
Australia does not publish details on the nationalities of the 1,152 people held on Manus and Nauru though refugee advocates said there are approximately 150 Sri Lankans detained. Many of these would have received their refugee status, advocates said, but for those who have been rejected, they face the choice of accepting the offer of cash from Australia or the threat of deportation.
Watch What Else Is Making News
“They are welcome to return to Sri Lanka and we won’t prosecute them,” Wickremesinghe told reporters in Australia’s capital Canberra. Despite the assurances from Wickremesinghe, refugee advocates said many Sri Lankans would be reluctant to return home amid reports of mistreatment of members of the ethnic Tamil minority, a claim Wickremesinghe rejected.
“It is quite safe for them to come back… we want all the Tamils to come back,” said Wickremesinghe.
The United Nations has urged Sri Lanka to better protect minorities like Tamils and redress the wrongs committed during a 26-year conflict with Tamil rebels which ended in 2009.

FILE PHOTO: Refugee advocates react as they hold placards and yell slogans during a protest in central Sydney, Australia, October 5, 2016 calling for the closure of the Australian detention centres located in Nauru and Manus Island. REUTERS/David Gray
SYDNEY The future of an Australia's controversial asylum-seeker detention centre in Papua New Guinea will be discussed during a two-day visit by Australian Prime Minister Malcolm Turnbull to the Pacific island nation starting Friday.
Australia is under pressure from human rights groups and the United Nations to close its two Pacific island detention centres, which have been widely criticised for cramped conditions, inadequate medical care and violence.
The Papua New Guinea Supreme Court ruled last year that the country's Manus island detention centre should close, forcing Australia and its Pacific island ally to confirm it would close the camp during 2017.
"The primary reason for Turnbull's visit is to discuss economic prospects but the topic of Manus island will be addressed too," a source familiar with the visit told Reuters on Thursday.
Turnbull's trip to Papua New Guinea comes a day after he met with Baron Waqa, the president of Nauru, and thanked him for hosting Australia's second detention centre in the Pacific.
Waga later met Australian Foreign Minister Julie Bishop to discuss the future of Nauru after the detention centre closes, though no timetable was given for the closure.
"We want to look at the economic opportunities for Nauru post the regional processing centre," Bishop said at a meeting Waqa in Sydney.
Australia has a strict policy of not allowing anyone who tries to reach the country by boat to settle there, instead detaining them in the Pacific camps, where asylum claims processing can take years, and even if they are found to be genuine refugees they are still barred from Australia.
Australia agreed with former U.S. President Barack Obama late last year for the United States to resettle up to 1,250 asylum seekers held in the Australian-funded camps. In return, Australia would resettle refugees from El Salvador, Guatemala and Honduras.
Any person not settled will be given the choice of residency in PNG or a 20-year visa on Nauru.
Turnbull's visit to Papua New Guinea will overlap that of the U.S. Department of Homeland Security, which begun collecting biometric information of some of the near 900 men held on Manus Island earlier this week.
U.S. officials collected similar information from asylum seekers on Nauru late last month, a move that reassured observers that despite U.S. President Trump describing the asylum seeker deal with Australia as "dumb", the deal was at this stage proceeding.
After leaving Papua New Guinea, Turnbull will travel to India where he will seek to advance trade between the two countries. Trade between Australia and India was worth nearly A$20 billion ($15.08 billion) last year and both nations hope to accelerate it with a free trade agreement.
($1 = 1.3266 Australian dollars)
(Reporting by Colin Packham; Editing by Michael Perry)


Question: i found this news title. can you represent it to find an explanatory news article?!

Question: Officials release photo of mock IED found at Toronto airport

TORONTO (AP) — U.S. customs officials released a photo Monday of a mock improvised explosive device that led to delays at Toronto’s Pearson International Airport when it was found in a passenger’s luggage this month.
U.S. Customs and Border Protection tweeted the photo and praised the officers who spotted the device on April 6. The photo shows electronic components apparently wired to a circuit board with a timer display and coils of wire snaking to bound-together cardboard tubes.
The discovery during an inspection at the airport’s pre-clearance area caused what was described as a major security breach.
Passengers on a United Airlines flight to Chicago were stuck on the tarmac for more than four hours.
Joseph Galaska, a 58-year-old American from the Milwaukee, Wisconsin, area was charged with one count of mischief. He was released on bail and his case is due back in a Toronto-area court Tuesday, though his lawyer said he’s not expected in person. Police said the mock device was not terrorism related.
Galaska’s wife has told ABC News the device found was an alarm clock.

represent the article to find a fitting news title

For example, ['Represent this text to find a news title for it', "While some would compare Drew Pearce’s world in ‘Hotel Artemis’ to the apocalyptic settings of ‘Mad Max’ & ‘I Am Legend,’ the director and screenwriter’s inspiration behind the scenery will not be what you’d expect!\nLongtime screenwriter and producer Drew Pearce is making his directorial debut with Hotel Artemis, a film he also wrote and filled with some of the best talent Hollywood has to offer. While the Jodie Foster-lead movie takes place in a riot-torn Los Angeles in the year 2028, Drew wouldn’t necessarily refer to his imaginary setting as a “dystopian” environment. “I was literally thinking, ‘What will L.A. look like in 10 years time?'” Drew laughed, while talking to HollywoodLife at a Cinema Society-hosted screening at Quad Cinema in NYC. “The scary thing is that what comes out is a movie that people say, ‘Oh, it’s a terrifying dystopia!’ But, let’s face it, if you’ve spent any time in Los Angeles, you absolutely know there could be a water riot any second!” Ha!\nFor his first directing gig, Drew inspired the likes of Foster, Sterling K. Brown, Sofia Boutella and Dave Bautista to star. Hotel Artemis follows Foster as The Nurse who runs a top-secret hospital for criminals called Hotel Artemis, which starts to fill up in the midst of riots and chaos in futuristic Los Angeles. “I’ve been on big films and written big films, but, this was my first as a director, and I’m working with a lead actress who has been acting for 52 years, so already, she’s been on more sets, worked with more directors than I ever will be in three lifetimes,” Drew explained. “On one level that’s intimidating, while on the other it’s incredibly exciting. One thing I do know is that Jodie, Sterling and the whole gang are really good at what they do.”\nDrew continued to praise his cast at the after-party celebration of the film, which hits theaters on June 8. The fete took place at Society Café at Walker Hotel Greenwich Village where attendees sipped Qui tequila cocktails named after the movie!"] should be similar to ['I found this news title. Can you represent it to find an explanatory news article?!', '‘Hotel Artemis’ Director Drew Pearce Reflect On Dystopian Los Angeles']

'Get down or I'll shoot': Police in standoff with suspected driver of Toronto van incident


Question: Represent this title to get a news article that provides more details about it

Question: Rodgers-led Packers beat Lions 31-24 to win NFC North

0:38 Scene of stabbing death on Ninth Street Pause
0:52 Huge fight greets holiday shoppers at Modesto's Vintage Faire Mall
1:02 Giving Tree campaign at mission
0:33 Stabbing in central Modesto leaves one man dead
2:43 Frank Carson emerges from jail to cheers from family and friends
0:40 Parade float up in flames because of cigarette thrown out car window
1:54 Why we make New Year's resolutions
2:04 Gear up for food safety to prevent food poisoning
1:41 New UC Davis coach, MJC coach share stage

Skip in Skip x Embed x Share CLOSE Free Press sports writers Dave Birkett and Carlos Monarrez preview the Lions-Panthers game. Can the Lions improve to 4-1 on Sunday at Ford Field?
Matthew Stafford runs for a first down in the third quarter of the Lions' 30-26 loss to the Falcons on Sunday, Sept. 24, 2017 at Ford Field. (Photo: Kirthmon F. Dozier, Detroit Free Press)
Detroit Lions (3-1) vs. Carolina Panthers (3-1)
When: 1 p.m. Sunday.
Where: Ford Field.
TV: Fox (Channel 2 in Detroit).
Radio: WJR-AM (760; other radio affiliates).
Line: Lions by 3.
Kickoff weather forecast: Partly cloudy, 77 degrees (Ford Field is a domed stadium).
Game notes from Associated Press: The Panthers and Lions are tied atop divisions and among six NFC teams with 3-1 records. ... Ameer Abdullah had career-high 94 yards rushing against Minnesota and 109 yards of offense, trailing only his 120-yard game last year against Indianapolis. … Matt Prater is the first NFL kicker with five field goals of 55 yards or longer in single season. ... QB Cam Newton won franchise-record 54th game last week against Patriots. Newton was 22 for 29 for 316 yards with three TDs, one INT and ran for score to extend NFL QB record with 50 rushing TDs.
More:
The Road to XII: How 2017 Detroit Lions will win 12 games
Lions vs. Panthers: Scouting report, prediction for Sunday
Twitter updates
Live updates for mobile users.


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Londoner’s newest single cracks Top 40

This news article should be represented to find a fitting news title.

This is a year Genevieve Fisher is unlikely to forget.
First, the 25-year-old country singer-songwriter saw her song, Take It On Home, break through the Top 40 country music charts after four successive songs reached the Top 50.
A month later Fisher won the country music category at the Jack Richardson London Music Awards.
Then, the Country Music Association of Ontario announced Fisher and London native Jessica Mitchell were both nominated for the association’s female artist of the year award, later won by Meghan Patrick.
And, now, Fisher’s newest single, You Me We, is her second consecutive single to break into the Top 40, up against Canadian and American country stars.
“It’s just been amazing,” said Fisher, who also found time along the way to get married to Brian Shaw.
“This year’s been crazy.
How far You Me We will climb is anyone’s guess. So far, Fisher said it’s been a “roller coaster ride” with the tune.
“Every song is different and you never know what’s going to happen,” Fisher said. “This was a tough song. I was getting worried because it wasn’t getting picked up (by radio stations) but then all of a sudden they started playing it.”
Other songs by Fisher that made the Top 50, but not beyond, include July (2012), Shut Down This Day (2013), Bad Enough (2013) and Night In Night Out (2014).
The graduate of Western University’s Don Wright Faculty of Music was identified by the TopCountry.ca website, as one of the emerging country artists to watch in 2017 and she has not disappointed.
To date, there is no plan to put out an album. Fisher is an independent artist not signed to a label.
“I want to make sure I’m putting out songs that I really want to sing,” said Fisher, who’s not opposed to signing with a label.
“So I feel like there’s more pluses to be an indie artist right now because you have the freedom to do what you want and when you want to do it.”
Fisher said her calendar for next summer’s festival season is “packed” and she hasn’t yet heard if she’ll be performing at this year’s Country Music Association of Ontario’s awards gala being held in London June 3 at Centennial Hall.
“I’m not sure, but I would love to,” said Fisher. “It’ll be an interesting year and we’ll have to wait and see what happens.”
jbelanger@postmedia.com
Twitter.com/JoeBatLFPress

Represent the article to find a fitting news title

As we ring in 2017, let's celebrate with songs that peaked at No. 17 on the Billboard Hot 100.
Start the conversation, or Read more at Billboard.


Question: Represent this title to get a news article that provides more details about it

Question: Melania Knew Exactly Which Outfit To Whip Out of Closet Before Meeting President of France

First lady Melania Trump’s outfit choice stole the show as she and President Donald Trump hosted French President Emmanuel Macron and his wife Brigitte for the administration’s first official state visit.
The first lady’s wide-brimmed hat and matching Michael Cors white outfit stood out against the overcast sky during Tuesday morning’s pomp-filled ceremony on the White House’s South Lawn.
As was readily apparent during the Trumps’ visit to Paris last summer, Melania and Brigitte coordinated their outfits for the occasion.
The U.K. Daily Mail reported the French president’s wife wore a Chanel-style boucle dress and jacket, also in white.
Social media lit up with speculation that Melania Trump’s hat was a subtle nod to Beyoncé Knowles’ chapeau in her 2016 “Formation” video from her “Lemonade” album about her husband’s unfaithfulness, according to USA Today.
Others thought it was an ode to the outfit worn by the fictional Olivia Pope (played by Kerry Washington) in the television show “Scandal.”
Melania and Brigitte made a fashion statement on Monday as well, when the French first couple paid a visit to the White House.
“Melania gave a nod to some of the biggest designers from her guest’s home nation, wearing a $2,790 Givenchy tuxedo cape, Christian Louboutin heels, and a Christian Dior purse. She paired them with a dress by Italian designer Dolce & Gabbana,” the Daily Mail reported.
Meanwhile, Brigitte donned a Louis Vuitton ensemble, featuring a pale yellow coat worn over a matching dress.
President @realDonaldTrump and @FLOTUS Melania Trump, along with French President @EmmanuelMacron and his wife Brigitte Macron, plant a tree on the South Lawn of the @WhiteHouse. The tree, a European Sessile Oak, was provided by the Macrons as a gift. pic.twitter.com/zQIWT2Cmdz — Fox News (@FoxNews) April 24, 2018
Do you think Melania Trump was trying to send a message with her hat choice? Yes No Continue with Facebook -- or -- Completing this poll entitles you to The Western Journal news updates free of charge. You may opt out at anytime. You also agree to our Privacy Policy and Terms of Use You're logged in to Facebook. Click here to log out.
Melania and Brigitte stood by as their husbands planted an oak tree on the South Lawn.
The tree, a gift from the Macrons, comes from Belleau Wood in France, which was the site of a major battle involving U.S. forces during World War I in June 1918.
RELATED: Trump Shuts Democrats, Media Out of First State Dinner
Over 9,000 Marines gave their lives fighting alongside French and British allies during the fierce fighting in the months leading up the to end of the war.
Following Tuesday’s ceremony, the first ladies headed to the nearby National Art Gallery for a guided tour by curator Mary Morton.
Later in the evening, the Trumps will host the Macrons in the administration’s first official state dinner, which will include approximately 150 guests.
Melania Trump reportedly oversaw the planning of the event herself in coordination with the White House staff. Previous recent first ladies have brought in outside event planners for state visits.
PRESIDENTIAL WELCOME: Tables are set at the White House, where Pres. Trump will host French Pres. Macron with a lavish state dinner tonight. https://t.co/aatbseV2qP pic.twitter.com/avCZuDaEK1 — ABC News (@ABC) April 24, 2018
The Hill reported the menu will consist of three courses, with both American and French fare.
The main course will be a spring lamb with Carolina gold rice jambalaya.
The wines to be served were made in Oregon using French grape plants.
What do you think? Scroll down to comment below.

Represent this text to find a news title for it.


Question: Represent this title to get a news article that provides more details about it:

Question: Expanded Conference Glance

August 2017 S Sunday M Monday T Tuesday W Wednesday T Thursday F Friday S Saturday
Golden Acorn Casino Promotion!
Cottage View
IID
Caliber Collision
Wellness Radio
Behavioral Health Services


Question: I found this news title. Can you represent it to find an explanatory news article?:

Question: Craegmoor Supporting You in the Midlands

Represent this text to find a news title for it

Cookies at Which? We use cookies to help improve our sites. If you continue, we'll assume that you're happy to accept our cookies. Find out more about cookies
OK

Stay up to date on all the latest result news with The New Indian Express App. Download now


Question: represent this title to get a news article that provides more details about it

Question: The Baseball Report: Manaea Records First No-Hitter Of Season

Ryan Mayer
Three weeks into the MLB season, and we’ve already got our first no-hitter. And it came against an unlikely source. The Oakland Athletics are off to a solid start to the season, sitting at 12-11 and just 3.5 games back of the Astros in the American League West division standings. However, heading into this past weekend’s series against the Boston Red Sox, you would have been forgiven if you believed that Boston would dominate the A’s. The Red Sox had burst out of the gates to a 16-2 record prior to the series, and there wasn’t much that could seemingly slow down their bats.
Then, in stepped A’s lefty Sean Manaea. The 26-year-old had a solid debut season in 2016 before falling off a bit during last year’s campaign. To begin this season, Manaea was dominant, giving up just 5 earned runs through 27.2 innings pitched, while striking out 20 batters and giving up just four walks. In his Saturday start against Boston, he did even better, striking out 10 with just two walks and not allowing a hit through nine innings. It was his first career no-hitter and the first for the A’s since Dallas Braden threw a perfect game on Mother’s Day of 2010.
There was some controversy in the game, as Red Sox outfielder Andrew Benintendi appeared to record a hit in the sixth inning, but he was ruled to have run out of the base path after instant replay. Manaea now owns a 1.23 ERA, which ranks fifth in the league so far this season.
The leader in that category is San Francisco Giants righty Johnny Cueto, who is experiencing a bounce-back season. Through four starts, Cueto has allowed just one earned run in 26 innings of work, while striking out 23 batters. In his Sunday start against the Angels, Cueto allowed just two hits and struck out seven, earning his second win of the season. He looks well on his way to returning back to his career form after struggling through last season, when he posted his highest ERA since his first year in the majors.
For these and some of the other biggest stories from the past week of baseball, click on the video above.

Represent the article to find a fitting news title.


Question: Represent the title to find an explanatory news article:

Question: How PolitiFact won over SpaceX founder & media-critic Elon Musk

Represent this text to find a news title for it.

FILE - In this Dec. 2, 2015, file photo, Tesla Motors Inc. CEO Elon Musk delivers a speech at the Paris Pantheon Sorbonne University as part of the United Nations Climate Change Conference in Paris. For years, Tesla has boasted that its cars and SUVs are safer than other vehicles on the roads, and CEO Elon Musk doubled down on the claims in a series of tweets this week. Francois Mori, File AP Photo

“It’s easy, at a time of rolling scandals and hourly push alerts, to lose sight of how extraordinary this moment is,” CJR Editor and Publisher Kyle Pope writes in the opening pages of our new print issue. The past year has been unlike any the US political world has ever seen. Donald Trump’s rise from reality-TV celebrity to reality-TV president challenged and changed journalism in myriad ways. CJR’s fall magazine looks at the people, moments, and news organizations Trump’s presidency has affected.
From Ivanka to “the dossier” to a moment of reckoning for the political press, the issue tackles some of the biggest personalities and existential questions that have become part of the daily conversation in Washington.
In the days to come, we’ll be posting great pieces, including CJR’s Pope on his time as editor of The New York Observer under Jared Kushner (which publishes on cjr.org at noon today), McKay Coppins on the threat posed by right-wing media, Collier Meyerson on covering a country where race is everywhere, and many more. So keep checking in as we roll out the new issue, and if you’re not already a member, we’d be grateful for your support—$50 gets you a year of access to exclusive content, four issues of the print magazine, and invitations to CJR events.
Below, the first few pieces we’ve already made available online.
Best press he’s ever had : In perhaps my favorite piece in the issue, former New York Daily News gossip columnist Lloyd Grove looks at Trump’s complicated and profitable relationship with tabloid journalism.
In perhaps my favorite piece in the issue, former New York Daily News gossip columnist Lloyd Grove looks at Trump’s complicated and profitable relationship with tabloid journalism. Trump and the Watergate effect : The Washington Post’s Margaret Sullivan wonders whether the work being done by journalists today will inspire the next generation of Woodwards and Bernsteins.
The Washington Post’s Margaret Sullivan wonders whether the work being done by journalists today will inspire the next generation of Woodwards and Bernsteins. Can the First Amendment save us? : Columbia University President and First Amendment scholar Lee C. Bollinger writes about battles over press freedom and trust in the Trump era.
Columbia University President and First Amendment scholar Lee C. Bollinger writes about battles over press freedom and trust in the Trump era. When all the news that fits is Trump: Former New York Times Executive Editor Jill Abramson praises the work that journalists have done in the first year of the new presidency, but warns of the pitfalls of the Trump bump.
Other notable stories
Has America ever needed a media watchdog more than now? Help us by joining CJR today
Pete Vernon is a CJR staff writer. Follow him on Twitter @ByPeteVernon.


Question: Premier League 2017-18 - Week one round-up (pics)

this news article should be represented to find a fitting news title

It was an astonishing opening weekend in the Premier League with plenty of goals, a debut to remember and a goalscoring return for the prodigal son.
Romelu Lukaku’s dream debut for Manchester United saw the big Belgian net two of his side’s four goals against West Ham as the Red Devils go straight to the top of the fledgling league table. Former United striker Wayne Rooney also had a dream return to his hometown club Everton as he scored the only goal in the Toffees narrow win over relegation favourites Stoke City.
The champions had a day to forget at Stamford Bridge as they were beaten 3-2 by Burnley and saw both skipper Gary Cahill and Cesc Fabregas sent-off to leave boss Antonio Conte with questions to answer ahead of next weekends Wembley date with Spurs.
French striker Olivier Giroud scored a dramatic winner as Arsenal beat Leicester City 4-3 in an incredible match at The Emirates on Friday and new boys Huddersfield Town upset the form book to beat Crystal Palace 3-0 at Selhurst Park in their first top-flight game since 1972.
Liverpool boss Jurgen Klopp was angry at seeing his side throw away the lead at Watford despite another debut goal from Mohamed Salah, and Manchester City breezed to victory at another of the league’s new boys, Brighton & Hove Albion.
Check out our gallery for the best moments of the opening weekend:

GETTY Asmir Begovic expects Chelsea to bounce back from Manchester United loss
Chelsea's 2-0 loss at Manchester United saw their lead over second-place Tottenham cut to just four points after Spurs thrashed Bournemouth 4-0 over the weekend. It meant Chelsea have now lost two of their last four Premier League games, while Spurs are on a seven-game winning streak. But Begovic is confident Chelsea can remain in pole position for the remainder of the season as the majority of the Chelsea squad consist of players that won the title in 2014-15 campaign.
REUTERS Asmir Begovic couldn't keep out Manchester United in Chelsea defeat
"It's not getting nervy. We are an experienced group of players who have been there and done this before," Begovic told the club's website. "We have to just focus on getting better for the next game." Begovic insists Chelsea are still in a good position after their defeat at Old Trafford and urged his team-mates to focus on themselves instead of Tottenham.
Premier League title odds 2016/17 Sun, April 16, 2017 Express Sport runs through the best available Premier League 2016/17 title odds found on www.oddschecker.com Play slideshow GETTY 1 of 7 Click to reveal the best Premier League 2016/17 title odds from oddschecker.com


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q2 2017 Results - Earnings Call Transcript

represent the article to find a fitting news title

Cellectar Biosciences, Inc. (NASDAQ:CLRB)
Q2 2017 Earnings Conference Call
August 14, 2017 05:00 PM ET
Executives
Jules Abraham - JQA Partners
Jim Caruso - CEO
Chad Kolean - VP and CFO
John Friend - VP and CMO
Jarrod Longcor - SVP of Corporate Development and Operations
Analysts
Wangzhi Li - Ladenburg
Operator
Good day, ladies and gentlemen and welcome to the Cellectar Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]
I would now like to turn the call over to Jules Abraham with JQA Partners. Please go ahead.
Jules Abraham
Thank you, operator. Good afternoon and thank you for joining us today to review the financial and operational results of Cellectar Biosciences for the second quarter of 2017 on this conference call and live webcast. Earlier today, the company filed its financial statements with the SEC for the quarter ending June 30, 2017 which can be found both on the SEC website and the Investor Relations section of the company's website at www.cellectar.com. In addition, a replay of this conference call will be available on the company website.
Joining me today from Cellectar are Jim Caruso, Chief Executive Officer; Chad Kolean, Cellectar's Vice President and Chief Financial Officer; John Friend, M.D., Vice President and Chief Medical Officer and Jarrod Longcor, Cellectar's Senior Vice President of Corporate Development and Operations.
Before I turn the call over to Mr. Caruso, please note that some of the remarks you will hear today may contain forward-looking statements about the company's performance. In addition, there may be forward-looking statements during the Q&A session following prepared remarks. These statements are neither promises nor guarantees and there are number of risks and uncertainties that could cause actual results to differ materially from those set forth in these forward-looking statements. Additional information concerning factors that could cause actual results to materially differ from those in these forward-looking statements is contained in the company's filings and periodic reports filed with the SEC. Copies of which are available on the company's website or maybe requested directly from Cellectar. Forward-looking statements are made as of today's date and the company does not undertake any obligation to update any forward-looking statements made during today's call.
With that said I now turn the call over to Mr. Caruso. Jim?
Jim Caruso
Thank you Jules and thank you to all participants for joining us today for a review of our second quarter 2017 financial and corporate results. We have continued to realign our investments into programs with the greatest potential to accelerate Cellectar's growth and development and are encouraged by the pace of this repositioning and execution on our strategic plan. The CLR 130 clinical data observed to-date have been promising and we look forward to announcing additional results from our Phase I and Phase II trials. We are also driving value creation through strategic collaborations to enrich the company's small molecule pipeline with proprietary assets. To this end, we remain pleased with our ongoing relationship with Pierre Fabre and the progress achieved developing new PDCs, utilizing the proprietary payloads provided by Pierre Fabre. Two weeks ago we announced our collaboration with Avicenna Oncology, a leading cancer targeting research and development company. This deal is also strategically important to Cellectar on multiple levels and Jarrod Longcor, Senior Vice President of Corporate Development and Operations will further provide details later in the call.
In a parallel path, we continued to drive our lead PDC program, CLR 131, currently in a Phase 1 trial for multiple myeloma to establish the drug's maximum tolerated single dose and in a Phase II for multiple myeloma and other orphan designated blood cancers with the potential for a second dose. We continue to be encouraged with the drug's performance and John Friend, our Chief Medical Officer will provide study details as well as further updates on this program. Throughout the last two years, we have also achieved 16 intellectual property milestones which further protect our PDC platform and proprietary PDCs in the US as well as other strategic countries. It is also important to reiterate that each new PDC will be viewed as a new chemical entity. From a financial perspective, we maintain our guidance that our cash on hand will allow us to maintain operations into the second quarter of 2018. CFO Chad Kolean will provide further details including a full financial summary of our second quarter. I will then provide closing comments, after which the entire executive team will be available to answer your question.
At this time, I'd like to turn the call over to Cellectar's CFO Chad Kolean for an overview of the first [ph] quarter 2017 financials.
Chad Kolean
Thank you, Jim. Before discussing our results for the second quarter, I want to comment on the special meeting of stockholders that will be held on September 12 at our offices here in Madison as it is an important process for all of our investors. The reason for the meeting is to fully and completely address any concerns that may arise regarding the vote that increased our authorized shares to 80 million as part of our May 31 Annual Meeting. I want to make it clear that the only purpose of this special meeting is to ratify or affirm the vote from the annual meeting where investors approved the increase in the number of authorized shares. In other words, the proposal being voted on at the special meeting on September 12 does not represent any new action by the company whatsoever. It is entirely focused on ensuring that the stockholders approval was made based upon a clear understanding of that proposal. In the proxy document that we sent to all stockholders in preparation for the annual meeting in May, there was an inadvertent drafting error that could have caused confusion for the reader.
In particular, the May proxy statement suggested that brokers and other nominees who hold shares in Street name on behalf of their clients would not have discretionary authority to vote those shares with respect to the approval of the proposal to increase to share authorization to 80 million even though it had been the company's intent to state that consistent with the applicable rules, discretionary voting is permitted. As a result and to ensure that there is no concern or confusion regarding the communications with stockholders prior to the annual meeting, we decided to ask stockholders to ratify the vote in the upcoming special meeting which is the sole purpose of that meeting. The management team and the company's Board of Directors ask that you review the materials when you receive them and recommended that you support the company by voting for the proposal.
Now I want to turn to our operating results for the second quarter of 2017. Research and development expenses were 2.2 million, an increase of 1.2 million from the prior year. We undertook two substantial initiatives last year, the primary drivers of this increased spending. The first is the Phase II clinical trial in hematologic malignancies that we initiated at the end of the first quarter and the second is the establishment of a production capability that can address the increased CLR 131 for ongoing and any future clinical trials as well as adequately provide product to support commercialization. Both of these initiatives are incremental to our ongoing Phase I relapse refractory both for myeloma clinical trial for which the expense was relatively consistent with the prior year were 1.0 million in the quarter just ended, an improvement of 0.3 million from the second quarter of 2016. The reduction in expense was primarily a result of lower professional fees for consulting, legal and accounting services.
As a result of our increased R&D spending, our loss for operations increased to 3.2 million for the second quarter of 2017 as compared to the second quarter of 2016 when our operating loss was 2.3 million, this increase was entirely planned by the company. Other income for the current quarter was 0.1 million, while other income was 0.2 million for the second quarter of 2016. The small gains for both periods were primarily a result of non-cash adjustments to the value of certain securities treated as derivative liabilities on the company's balance sheet. Our loss for the quarter was 3.1 million or $0.23 per share. For the second quarter of 2016, the net boss was 2.1 million or $0.49 per share. On June 30, 2017, we had 8.3 million in cash and cash equivalents on hand, while as of December 31, 2016, we had 11.4 million in cash and cash equivalents. We are reaffirming our estimate that our available cash and cash equivalents should fund the company's planned operations into the second quarter of 2018. Additional capital will be required to complete planned pre-clinical research and further clinical development of key assets.
And now I will turn the call back over to Jim.
Jim Caruso
Thank you, Chad. As you know we are now in the fourth cohort of our Phase I MTD trial of CLR 131 for the treatment of relapse refractory multiple myeloma and have initiated our NCI-supported Phase II trial as well.
John Friend will now provide us with an update on those clinical programs.
John Friend
Thank you, Jim. Good afternoon everyone, although we have witnessed great advances over the past decade in the treatment of various cancers, the resistance and refractory nature of multiple myeloma and other B-cell malignancies has posed a very challenging hurdle to overcome. Often the time progression accelerates after each successive round of therapy or trying a new agent or combination thereof. Given that, currently there are limited treatment options available that offer a significant improvement on overall survival in the refractory setting. And based on the clinical data already observed with a single infusion of CLR 131 in heavily pretreated or relapsed refractory patient population, we remain optimistic regarding the potential benefit CLR 131 may provide to patients living with cancer. As Jim stated, I would like to provide you with a review of our ongoing clinical study.
As a reminder, the current Phase I study is an open label dose escalation study in relapsed or refractory multiple myeloma patients. The primary objective of the study is to determine the safety and tolerability of a single 30- minute infusion of CLR 131 with and without dexamethasone. These early studies help guide us in the choice of a dosing regimen to move forward into Phase II and frequently provide us with a hint of potential efficacies that shows improved progression free survival and overall survival. We believe that based on our evaluation to-date both safety and efficacy signals continue to be extremely encouraging. The safety and efficacy of the third cohort was presented at the first quarter call three months ago and I'm pleased to say four cohort is fully enrolled. These patients receive 31.25 millicurie per meter squared to the compound and we expect to report initial results from this cohort by the close of third quarter 2017, in line with our previous guidance.
As for the remaining cohorts, after a single infusion of 12.5 millicurie per meter squared, patients in the first cohort have achieved an impressive median overall survival of 22.5 months to-date. Patients from the second and third cohorts who received 18.75 millicurie per meter squared and 25 millicurie per meter squared doses have experienced median overall survival of 13.2 months and 6.7 months respectively. We continue to collect overall survival on all evaluable trial participants and will provide timely updates as appropriate. With regard to NCI supported Phase II study of CLR 131 in multiple myeloma and other hematologic malignancies, we initiated the trial on March 30, 2017 and it is active and enrolling. It is being conducted at approximately 10 to 15 top cancer centers across the United States for patients with a variety of orphan designated relapse or refractory hematologic cancers. The study's primary endpoint is clinical benefit rate with additional informative secondary endpoints of overall response rate, progression free survival, median overall survival and other markers of efficacy.
Similar to our Phase I study, all patients will receive a single 25 millicurie per meter squared dose of CLR. But unlike the Phase I study, an optional second dose of 25 millicurie per meter squared can be infused approximately 75 to 180 days later. The hematologic cancer studied in the trial include multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, and potentially diffuse large B-cell lymphoma.
In addition to the CLR 131 infusion, multiple myeloma patients will receive 40 milligram oral dexamethasone weekly for up to 12 weeks. Efficacy responses will be determined by the latest International Multiple Myeloma Working Group criteria. Efficacy for all lymphoma patients will be determined according to the Lugano criteria. We look forward to provide an update on both of these trials as they become available.
With that, it's my pleasure to turn the call over to Jim.
Jim Caruso
Thank you for the summary of our progress with CLR 131, John. As we consistently state, our clinical focus remains on the successful execution of the development of CLR 131 for the treatment of relapsed, refractory multiple myeloma and other select hematologic malignancies. We're very pleased with our continued momentum toward that and look forward to sharing future updates.
At this time, I'd like to turn the call over to Jarrod Longcor, Cellectar's Senior Vice President of Corporate Development and Operations to discuss our Pierre Fabre and Avicenna Oncology collaborations as well as an update on select pre-clinical programs.
Jarrod Longcor
Thank you, Jim. As was mentioned by Jim earlier in this call, we have focused both our partnering and research and discovery strategies on long-term value generation. This will come in the form of revenues via upfronts, milestones and royalties as well as access to molecules, or payloads for the PDCs that Cellectar can develop on its own or in collaboration, additionally defraying R&D expenditures and providing more details in general for the company.
To this end, both Pierre Fabre and our recently announced collaboration with Basel, Switzerland based Avicenna Oncology provides such strategic benefits. The deal with Avicenna provides a unique opportunity to collaborate with experts in the antibody drug conjugation or ADC delivery field and further validate our next generation delivery platform with new proprietary payloads to potentially create new products for the treatment of various solid tumors.
As part of the collaboration, we will examine the two delivery modalities side-by-side with the same payload, which will provide Cellectar with an opportunity to further validate the PDC platform and to generate key data that would differentiate this method of targeted delivery versus that of the antibody drug conjugates, which we believe will further demonstrate that our PDC platform is the next generation of targeted therapies. Under the terms of the deal, Avicenna will provide their novel chemotherapy payloads through Cellectar.
We will then leverage our expertise and chemical conjugation to link the molecules through our phospholipid ether or PDC platform and put these molecules through our rapid iterative in vitro and in vivo screening process to identify the best PDC. These PDCs will then be tested alongside the previously designed ADC or antibody drug conjugates with the same payload provided by Avicenna.
Additionally, the collaboration allows both companies to have the option to advance the development of any of the newly congregated molecules, PDCs, either globally or regionally. Therefore, this collaboration also provides Cellectar with a very interesting and potent payload to which we would not otherwise have access. We look forward to combining our respective companies' expertise to better understand the potential benefits of our next generation targeting platform PDCs versus that of the ADC delivery.
With regard to our collaboration with Pierre Fabre, we continue to make significant advances. We have identified a select number of PDCs that show the potential to have the preferred therapeutic window and potential efficacy. In terms of our other preclinical activities, we have expanded our PDC research to include a new program involving a novel payload internally. Furthermore, we continue to strengthen our research capacity to leverage our CLR CTX conjugate programs to allow future collaboration as well as our own in-house proprietary small molecule research. We also remain focused on broadening the potential of CLR 131 and continue to perform research to identify optimal dosing regime, tumor types and ideal drugs to be used in combination with CLR 131.
Over the preceding quarter, we completed a handful of in vivo experiments, evaluating CLR 131 in various solid tumors, including ovarian, prostate, bladder, lung cancer and Glioma. CLR 131 has shown excellent activity in each of these models as a single agent. In addition, we have explored the use of multiple doses in several of these tumor types. Here again, we have seen that CLR 131, when given in multiple doses, and/or fractionated doses of two or three doses provide excellent single agent effect with an even greater efficacy over the single dose, including a greater than doubling of survival in several solid tumor models. We expect to have further updates on all of these programs in the weeks and months to come.
I'd like to now return the call to Jim.
Jim Caruso
Thank you, Jarrod. As always, we look forward to announcing additional company milestones and events as they occur. In the meantime, I'd like to thank you very much for your participation on this call and your continued interest in Cellectar. At this time, Chad, John, Jarrod and I welcome any questions that you may have.
Question-and-Answer Session
Operator
[Operator Instructions] Our first question is from Wangzhi Li with Ladenburg. Your line is now open.
Wangzhi Li
Yeah. I have a few. Firstly, just touch on the Avicenna collaboration. So you mentioned one reason for the partnership that you can compare the PDC with the ADC head to head, just wonder if you can provide more color in terms of what exactly you can compare, what do you want to compare between the PDC and the ADC and why it's important for you?
Jim Caruso
Terrific. Great question, Wangzhi. We appreciate it. We're very excited about the Avicenna collaboration for a number of reasons. And the one question that you just cited is of particular interest for us as well as some other clear benefits to the company as well. The gentleman who orchestrated that collaboration is Jarrod Longcor and I'll ask him to provide additional color.
Jarrod Longcor
Thank you, Jim. Thank you, Wangzhi. I think the best way to describe, there's a host of data that will come out of that head to head comparison, but I think probably two of the key ones that will be beneficial to us is historically it's often been stated in literature and other places that with antibody drug conjugates, they see only about 1% of the material that gets to the exposed, to the tumor and it's exposed to the tumor, is actually taken up into tumor cells. One of the things we would like to see and we know that we're seeing a much higher rate of uptake than that with our molecule alone, so what would this allow us to do is see that in a exactly same molecule other than an antibody versus the phospholipid ether molecule. Everything else being the same, we'll see what the difference is in that uptake in CV potential enhancement of the uptake into the tumor with our molecule versus an ADC.
The other part of that is clearly more on the efficacy side, so obviously to deliver more to the tumor and into the tumor, therefore, we should see an increased efficacy and we look to see that as part of the outcome as well. Furthermore, we think that as we've talked about in the past, we believe these molecules, our PDCs provide an increase in therapeutic window, not only over the base, what I'll call parent molecule or what is the payload, when it's given by itself, but also in general potentially against the antibody drug conjugates, while they are targeted with an antibody, the epitopes that they target can also be on normal tissue as well.
Jim Caruso
I think - thank you, Jarrod. The only other elements I would add to that, just in terms of the benefits of this collaboration in general really gives us an opportunity to gather additional intelligence with real ADC experts as part of this compare and contrast and additionally, it really provides us access to proprietary molecules that provide us with the potential to create new phospholipid drug conjugates or PDCs, in this particular case, we believe high potential for the treatment of solid tumors.
Wangzhi Li
So maybe it's early, but any color in terms of potential timeline, do you get those type of data you just mentioned?
Jarrod Longcor
Yes. Sure. It is too early to say that. To be honest, the collaboration has really just been kicked off. As you know, we made the announcement, however, the real meat and potatoes of what we're going to be doing is going to be now down here in September when we really get started cranking through some of this and moving forward. So we hope to have some outputs, perhaps early next year to the middle part of next year sort of timeframe at this juncture and then going as fast as we can from that.
Jim Caruso
I will say this Wangzhi, based on the work of the team via our collaboration with Pierre Fabre, we really have put an infrastructure in place that now allows us to really accelerate the level of pre-clinical research from the conjugation of these compounds. And based on the relationships that we put in place internally as well as with third-party players, we can accelerate the research in this particular area. So we're excited about the collaboration and we think we'll be able to get more done sooner rather than later.
Wangzhi Li
And then shifting gear to another question on the Phase II trial, you mention the primary endpoint, benefits raised, could you clarify that means disease control rates or it's a different meaning?
Jim Caruso
So why don't I turn that over to Dr. Friend.
John Friend
Thank you, Wangzhi. Yes. You're correct. It is the disease control, which is a combination of complete response, partial response and stable disease. So you're correct. Yeah.
Wangzhi Li
And the last question is, for the two, you mentioned potentially included DLBCL, I just wonder you have more color in terms of when you will decide to include DLBCL or not and what's the criteria you're looking there?
John Friend
Yes. We did say potentially and I think that decision will come probably early 2018, the criteria in terms of diffuse B-cell, we are actually waiting, as you know, we are looking for those first three or four cohort groups to expand out to the diffuse B-cell at this point.
Jim Caruso
Said another way Wangzhi, we're really focusing on the other selected hematologic malignancies that John cited earlier in his review of CLR 131. Once we get our arms around because we believe those are the cleanest near-term opportunities for us, once we get a better understanding there, then we'll advance the program.
Operator
And I'm showing no further questions. I would now like to turn the call back to Jim Caruso for any further remarks.
Jim Caruso
All right. Terrific. Well, first of all, thank you to all of the participants. We certainly appreciate your continued interest in Cellectar, your continued belief in our technology, which we believe will have a meaningful impact on disease with high unmet medical need in the patients that suffer from these challenging diseases. Thanks again. We look forward to our next call.
Operator
Ladies and gentlemen, thank you for participating in today's conference. You may all disconnect. Everyone, have a good day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

Culp, Inc. released its quarterly earnings results on Tuesday. The textile maker reported $0.49 EPS for the quarter, topping the Zacks' consensus estimate of $0.45 by $0.04, Bloomberg Earnings reports.
Start the conversation, or Read more at AmericanBankingNews.com.


Question: Represent the title to find an explanatory news article

Question: Lin-Manuel Miranda Debuts All-Star Charity Song ‘Almost Like Praying’

Represent this text to find a news title for it:

Lin-Manuel Miranda has recruited an all-star lineup for his new track “Almost Like Praying.”
Marc Anthony, Ruben Blades, Camila Cabello, Pedro Capo, Dessa, Gloria Estefan, Fat Joe, Luis Fonsi, Juan Luis Guerra, Alex Lacamoire, John Leguizamo, Jennifer Lopez, Rita Moreno, Ednita Nazario, Joell Ortiz, Anthony Ramos, Gina Rodriguez, Gilberto Santa Rosa, PJ Sin Suela, Tommy Torres, and Ana Villafañe are all featured on the new song, which will raise money for hurricane relief in Puerto Rico.
Written by Miranda only last week, the original song borrows its title and instantly indelible hook from the classic show tune “Maria,” from West Side Story.
Check out the star-studded charity single below.

Whoa.. a bit too freaky for me! #AGT
RELATED CONTENT
WATCH: America’s Got Talent Golden Buzzer #1
Check Out How This Kindergarten Class Starts Each Day
Halsey Had To Be Treated By Medics At Her Show
ABC Has Cancelled “Roseanne” After Racist Tweet
WATCH: Man Scales The Side Of A Building To Save A Child Dangling From A Balcony
WATCH: An Interviewer Told Taylor Swift She Needed To Take A Shower…And Her Fans Do NOT Like It!


Question: Represent the title to find an explanatory news article!

Question: Musicians at South African memorial celebrate Hugh Masekela

JOHANNESBURG (AP) — Musicians in South Africa performed in a tribute for Hugh Masekela, the jazz musician and anti-apartheid activist who died after a decade-long fight with cancer.
The joyful memorial which drew about 400 people was held Sunday at the Soweto campus of the University of Johannesburg. Among those who performed were South African musicians Jonas Gwangwa, Sipho "Hotstix" Mabuse and Zimbabwean Oliver Mtukudzi.
"We knew he was famous, we knew he was great but we never ever thought he was (as) great as the world has shown us since his death ... how much it loved him," his sister Barbara told the crowd.
"Let us rejoice in the realization that Bra Hugh contributed meaningfully to humanity during his lifetime," said Nathi Mthethwa, South Africa's Minister of Arts and Culture. "Although he can no longer compose new songs, grace our stages and blow the trumpet, we know that his thundering voice will resound beyond the grave. Even death cannot silent his voice. Bra Hugh lives through his music."
Masekela died on Tuesday at the age of 78. The trumpeter, singer and composer started playing the horn at 14. He became an integral part of the 1950s jazz scene in Johannesburg and went to Britain and the United States in the 1960s, using his music to spread awareness about South Africa's oppressive system of white minority rule.
___
AP journalist Nqobile Ntshangase contributed to this report.

NBC staff have been celebrating the life of the late Salomon Salath //Hoeseb, since his death on Saturday.
Emotional staff of the NBC observed a moment of silence at NBC radio headquarters on Tuesday morning in honour of late Salomon Salath //Hoeseb.


Question: Represent this title to get a news article that provides more details about it:

Question: Swift justice: Jury takes Taylor’s side in groping lawsuit

represent this text to find a news title for it.

DENVER (AP) — Taylor Swift won $1 and long-awaited vindication Monday after a jury decided in a civil trial that a radio host groped her during a pre-concert photo op four years ago.
After a weeklong trial over dueling lawsuits, jurors determined that fired Denver DJ David Mueller assaulted the pop star by grabbing her backside during a backstage meet-and-greet. Swift hugged her crying mother after the verdict and reiterated how she wanted to stand up for other women.
“My hope is to help those whose voices should also be heard,” the singer said in a statement, acknowledging her ability to afford attorneys to defend her in court. “Therefore, I will be making donations in the near future to multiple organizations that help sexual assault victims defend themselves.”
The six-woman, two-man jury also found that Swift’s mother and radio liaison were within their rights to contact Mueller’s bosses about the groping.
Mueller sued the Swifts and their radio handler, Frank Bell, seeking up to $3 million for his ruined career. At the end of the trial, the judge dismissed Taylor Swift from Mueller’s lawsuit, saying he failed to prove that she sought to get Mueller fired or had any reason to believe that someone else may have assaulted her.
“I’ve been trying to clear my name for four years,” Mueller said after the verdict. “Civil court is the only option I had. This is the only way that I could be heard.”
The singer-songwriter said in her countersuit that she wanted a symbolic $1.
From the start, Swift’s side portrayed the encounter as a clear case of sexual assault, though they never reported it to police. Her mother tearfully testified that she asked Bell to reach out to Mueller’s employers at country station KYGO-FM instead because they wanted to handle the matter quietly and avoid exposing the singer-songwriter to publicity.
Bell contacted a station vice president and asked for an investigation of Mueller’s conduct. He also sent the station executive a photo taken of Swift, Mueller and Mueller’s then-girlfriend at the meet-and-greet.
In an hourlong stint on the witness stand last week, Swift blasted a low-key characterization by Mueller’s attorney, Gabriel McFarland, of what happened. While Mueller testified he never grabbed Swift, she insisted she was groped.
“He stayed attached to my bare ass-cheek as I lurched away from him,” Swift testified.
“It was a definite grab. A very long grab,” she added.
Mueller emphatically denied reaching under the pop star’s skirt or otherwise touching her inappropriately, insisting he touched only her ribs and may have brushed the outside of her skirt as they awkwardly posed for the picture.
That photo was virtually the evidence besides the testimony. In the image shown to jurors during opening statements but not publicly released, Mueller’s hand is behind Swift, just below her waist. Both are smiling. Mueller’s then-girlfriend is standing on the other side of Swift.
Swift testified that after she was groped, she numbly told Mueller and his girlfriend, “Thank you for coming,” and moved on to photos with others waiting in line because she did not want to disappoint them.
But she said she immediately went to her photographer after the meet-and-greet ended and found the photo of her with Mueller, telling the photographer what happened.
Andrea Swift testified that she asked Bell to call Mueller’s employers. They did not call the police to avoid further traumatizing her daughter, she said.
“We absolutely wanted to keep it private, but we didn’t want him to get away with it,” Andrea Swift testified.
Bell said he emailed the photo to Robert Call, KYGO’s general manager, for use in Call’s investigation of Mueller. He said he didn’t ask that Mueller be fired but that “appropriate action be taken.”
Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Represent this text to find a news title for it

0:59 Got flowers yet? Bellingham florist ready for Valentine's Day Pause
1:01 Rescued gulls are released at Tacoma Tideflats
4:11 What you need to know about the massive Oroville dam emergency in California
4:25 Seattle Channel segment examines rights of sanctuary cities, features undocumented mother of three
2:23 One arrest as protesters block DeVos from D.C. middle school
6:25 Prosecution gives opening statement in Jamison Rogayan rape trial
11:38 Jamison Rogayan faces cross-examination in serial rape trial
1:58 Judge declares mistrial in Jamison Rogayan serial rape case
2:25 Lummi community members prepare salmon to feed Standing Rock Sioux in North Dakota


Question: I found this news title. Can you represent it to find an explanatory news article?!

Question: - *** InsideWorld News Browser ***

This news article should be represented to find a fitting news title

Login to your account for
for advanced settings: Email: Password:
To see news on this page you need to be logged in.If you already have an account simply login to your accountIf you don't have an account we welcome you to signup to our news service at this page

Click for more article by Al OPecia ..
Newsbiscuit on Facebook
Newsbiscuit on Facebook
Search our Archives Search for:


Question: Represent the title to find an explanatory news article

Question: Activist fund Elliott ramps up pressure on South Korean auto giant Hyundai

FILE PHOTO: A Hyundai logo is seen at Hyundai of Serramonte in Colma, California, U.S., October 3, 2017. REUTERS/Stephen Lam/File Photo
By Ju-min Park and Hyunjoo Jin
SEOUL (Reuters) - U.S. activist hedge fund Elliott Management dismissed Hyundai Motor Group's restructuring plan as insufficient on Monday and called on the South Korean conglomerate to adopt a holding company strategy and appoint more independent board members.
Elliott disclosed this month that it holds more than $1 billion worth of shares in three key affiliates of Hyundai Motor Group and called for a "more detailed roadmap" on how the group will improve corporate governance, optimize balance sheets and enhance capital returns.
Stepping up its campaign against the South Korean carmaker on Monday, Elliott said it was unclear how the group's restructuring plan would benefit minority shareholders.
The giant autos-to-steel group last month announced a plan to streamline its ownership structure, responding to calls from the government and investors for greater transparency and better governance at family-controlled conglomerates, or chaebols.
"Elliott is encouraged that the Group has acknowledged the need for an improved ownership structure. However, the unwinding of the current circular shareholding by itself... lacks clear benefits to minority shareholders," Elliott said in a statement.
It said it holds more than 1.5 percent of the common shares in each of the three key affiliates of the country's No.2 conglomerate - Hyundai Mobis <012330.KS>, Hyundai Motor <005380.KS> and Kia Motors <000270.KS>.
Hyundai said in a statement that it would continue to communicate with investors including Elliott to explain the goals and needs of its reorganization plan.
It is Elliott's latest challenge to South Korea's family-run conglomerates after it forced Samsung Electronics Co Ltd <005930.KS> to increase shareholder returns in 2017, and comes amid a government campaign to boost investors' power in a country where shareholder activism is rare.
ACCELERATE HYUNDAI
Elliott said the Hyundai group should combine Hyundai Mobis with Hyundai Motor to create a holding company, and set up a clear policy for dividend payouts.
"We believe this is truly a unique opportunity to unlock significant value in Hyundai Motor Group that the founding family and the leadership of the Group have built over the decades," Elliott said in its presentation.
It laid out its plan for Hyundai in a 43-page presentation on a new website: https://www.acceleratehyundai.com
In its introduction, Elliott boasted of its "successful" 2016/17 campaign against Samsung Electronics, in which it also urged a restructuring of the business as a holding company. Samsung turned down Elliott's push for the holding company structure, but instead boosted dividends and canceled treasury shares.
Regardless of whether Hyundai adopts a holding company structure, Elliott demanded the cancellation of treasury shares in Hyundai Motor and Hyundai Mobis.
Elliott said Hyundai Mobis and Hyundai Motor each has as much as 6 trillion won ($5.6 billion) of excess cash, but they "have used valuable capital to fund many questionable investments" including the group's $10 billion bid to buy a plot of land in Seoul at a 217 percent premium over the land's appraised value.
"We believe that Hyundai Motor Group’s current balance sheet is out of balance," it said.
Elliott also proposed that the three affiliates add three independent board members each to improve the group's corporate governance, which it said "remains below global standards."
Kim Sang-jo, head of South Korea's anti-trust watchdog, said on Friday that he expected talks between Hyundai and Elliott would not be friendly, although Hyundai may have prepared for the U.S. fund coming to challenge it.
(Reporting by Ju-min Park and Hyunjoo Jin; Editing by Muralikumar Anantharaman and Susan Fenton)

(Adds Busch and Grupo Mexico )
March 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:
** Exxon Mobil has agreed to sell its operated upstream business in Norway to private equity firm HitecVision and oil company Point Resources for an undisclosed sum, it said.
** Greece has agreed that its main power utility, Public Power Corp (PPC), will sell some coal-fired plants as part of bailout reforms, two sources close to the talks said.
** French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer.
** Chinese property developer and hotel operator Goldin Properties Holdings Ltd said Chairman Pan Sutong had offered about $1.5 billion to buy its outstanding shares and delist the company.
** Japan's government named six investment banks to serve as underwriters for the sale of additional shares in Japan Post Holdings Co, which is partly aimed at funding the rebuilding of areas hit by the 2011 earthquake and tsunami.
** Brokerage Cowen Group Inc's shares surged 19 percent on Wednesday after Chinese conglomerate CEFC China said it agreed to acquire a stake of about 20 percent in the U.S. company for $100 million.
** An attempted merger between the German and British stock exchanges was struck down by European regulators, formally ending a deal that unravelled in the wake of Britain's vote to leave the European Union.
** Russia's Sberbank hopes to complete the sale of its Ukrainian subsidiary in May or June, a source with the bank said.
** The chairman of Indian miner Vedanta Resources said he had no plans to buy assets in South Africa from Anglo American or push for a board seat after announcing plans to buy a 13 percent stake in the mining giant.
** Finland's Amer Sports, which makes Wilson tennis rackets and Salomon skis, will buy U.S. ski maker Armada for $4.1 million, the company said.
** Australian retail group Premier Investments Ltd said it had purchased a 10.8 percent stake in department store owner Myer Holdings Ltd, but added it had no plans to make a takeover offer at this time.
** U.S. private equity group TPG Capital is weighing whether to make a takeover offer for Australia's Fairfax Media Ltd as the target proceeds with plans to spin off its real estate classified advertising arm, The Australian Financial Review reported.
** Euronet Worldwide Inc ramped up its fight against China's Ant Financial Services Group in trying to acquire MoneyGram International Inc, urging the U.S. government to closely scrutinize the rival Chinese bid saying it raises "significant national security risks."
** U.S. private equity firm KKR & Co LP is preparing a potential consortium bid for Australia's Quintis Ltd backed by the sandalwood plantation group's managing director, a source said.
** Family-owned German vacuum pump maker Busch hopes its increased offer for rival Pfeiffer Vacuum will allow it to start constructive talks with management after a previous attempt was rebuffed. (Compiled by Laharee Chatterjee in Bengaluru)


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Astros' Dallas Keuchel: Loses catcher, no problem

Keuchel (5-8) allowed two runs on five hits and one walk while striking out seven in Friday's 5-3 win over Texas.
Keuchel's batterymate, Max Stassi, left the game in the first inning after getting hit by a pitch on the hand, so it was up to backup Tim Fedorowicz to guide the left-hander through the 102-degree temperature in Arlington. And the duo handled it with aplomb. Keuchel struck out six of the first seven men faced, didn't allow a hit until the third inning, and lasted seven innings for the first time since May 13, which was also the last time he gave up fewer than five hits. The bearded lefty will look to make it four quality starts in five games when he faces the White Sox at home in Houston.

represent this text to find a news title for it

Cleveland Indians’ Danny Salazar turned to his change-up and off speed pitches to escape jams in the 3-1 win over the Minnesota Twins on Monday night.
More FOX Sports Ohio Videos Jensen says Indians pitching staff needs to find ways to get out of innings Arroyo: ‘It was a victory just get to get out there’ Price after Arroyo’s start: ‘I anticipate he’ll be more crisp next time out’ Welsh: Arroyo working on shaking the rust off Seth Jones was pleased with Blue Jackets rookie Gabriel Carlsson Gabriel Carlsson enjoyed his NHL debut More FOX Sports Ohio Videos